Quantum BioPharma Expands Public Relations and Investor Engagement Strategy

Quantum BioPharma Ltd. has strategically engaged two prominent firms to amplify its public relations and investor awareness initiatives, signaling a robust approach to market positioning and communication. Enterprise Canada Inc. has been retained indefinitely to develop a comprehensive media strategy, while Empire Market Ventures will focus on targeted investor marketing and outreach over a three-month period beginning February 7, 2025.

The company's strategic communications expansion comes alongside significant product development progress across multiple therapeutic areas. Key products in development include unbuzzd™, a rapid alcohol detoxification beverage slated for Q1 2025 availability, rekvry™ for alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment advancing toward Phase 2 clinical trials.

Of particular scientific interest is the company's lead compound, Lucid-MS, which has demonstrated promising preclinical results in preventing and reversing myelin degradation—the underlying mechanism of multiple sclerosis. This innovative approach could represent a significant advancement in neurological disorder treatment.

The company has also established a unique business model with Celly Nutrition Corp. for its over-the-counter alcohol detoxification product, unbuzzd™. Quantum BioPharma maintains a 25.71% ownership stake and will receive royalty payments of 7% on sales until cumulative payments reach $250 million, after which the royalty will decrease to 3% in perpetuity.

By simultaneously expanding its communication strategy and advancing its product pipeline, Quantum BioPharma is positioning itself as an emerging player in the biopharmaceutical landscape, with a focused approach to addressing challenging neurodegenerative and metabolic disorders.